The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension ...
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences ...
Breezebio Inc., formerly known as Genedit Inc., has closed $60 million in series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the ...
To overcome the challenges of current CAR T-cell strategies and enhance their efficacy and specificity for acute myeloid leukemia, researchers at the Sino-American Cancer Foundation and collaborating ...
Coming off a U.S. FDA approval of the first GLP-1 in pill format, Novo Nordisk A/S leaned further into oral drug delivery efforts, partnering with Vivtex Corp. to develop next-generation oral ...
CF Pharmtech Inc. has announced approval from China’s National Medical Products Administration (NMPA) of an IND application filed by subsidiary Changfeng Suyue Pharmaceutical (Guangzhou) Co. Ltd. for ...
U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated ...
Asahi Kasei Corp. offered to buy Aicuris Anti-infective Cures AG, expanding its infectious disease portfolio with a marketed cytomegalovirus product and a herpes treatment nearing an NDA.
The psychedelic and psychedelic-like drug space made another stride as Ataibeckley Inc. disclosed positive top-line data from a double‑blind, placebo‑controlled, first-in-patient phase IIa study ...
Kivu Bioscience Inc. has announced receipt of Human Research Ethics Committee approval and clinical trial notification clearance in Australia to initiate a first-in-human trial of KIVU-305, its ...
The BioWorld Biopharmaceutical Index finished 2025 up 24.07%, building slightly on its 23% gain recorded at the end of November. While the increase trailed the Nasdaq Biotechnology Index’s 32.4% rise ...
China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results